XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Fair Value of Financial Instruments    
Debt Instrument, Valuation Technique [Extensible Enumeration] us-gaap:ValuationTechniqueDiscountedCashFlowMember us-gaap:ValuationTechniqueDiscountedCashFlowMember
Level 3 | Market interest rate | Convertible promissory note, related party    
Fair Value of Financial Instruments    
Convertible & Non-convertible promissory note, related party 0.121  
Level 3 | Principal amount | Convertible promissory note, related party    
Fair Value of Financial Instruments    
Convertible & Non-convertible promissory note, related party 2,250  
Level 3 | Related Party Receivable | Market interest rate    
Fair Value of Financial Instruments    
Related party receivable measurement input 0.116  
Level 3 | Related Party Receivable | Fixed payment amount    
Fair Value of Financial Instruments    
Related party receivable measurement input 2,500  
Level 3 | Contingent consideration receivable, related party | Elusys Therapeutics | Market interest rate    
Fair Value of Financial Instruments    
Contingent Consideration   0.147
Level 3 | Contingent consideration receivable, related party | Elusys Therapeutics | Principal amount    
Fair Value of Financial Instruments    
Contingent Consideration   2,250
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Discount rate    
Fair Value of Financial Instruments    
Contingent Consideration   0.150
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Future revenue projections    
Fair Value of Financial Instruments    
Contingent Consideration   141,400
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Minimum earn-out payment rate    
Fair Value of Financial Instruments    
Contingent Consideration   0.03
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Minimum earn-out payment    
Fair Value of Financial Instruments    
Contingent Consideration   5,000